GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Cyclically Adjusted PB Ratio

Emergent BioSolutions (STU:ER4) Cyclically Adjusted PB Ratio : 0.20 (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Emergent BioSolutions's current share price is €4.313. Emergent BioSolutions's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €21.98. Emergent BioSolutions's Cyclically Adjusted PB Ratio for today is 0.20.

The historical rank and industry rank for Emergent BioSolutions's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:ER4' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.07   Med: 2.92   Max: 8.34
Current: 0.2

During the past years, Emergent BioSolutions's highest Cyclically Adjusted PB Ratio was 8.34. The lowest was 0.07. And the median was 2.92.

STU:ER4's Cyclically Adjusted PB Ratio is ranked better than
92.05% of 692 companies
in the Drug Manufacturers industry
Industry Median: 1.89 vs STU:ER4: 0.20

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Emergent BioSolutions's adjusted book value per share data for the three months ended in Mar. 2024 was €11.656. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €21.98 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Emergent BioSolutions Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Emergent BioSolutions's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Cyclically Adjusted PB Ratio Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.51 5.32 2.20 0.53 0.10

Emergent BioSolutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.31 0.14 0.10 0.11

Competitive Comparison of Emergent BioSolutions's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted PB Ratio falls into.



Emergent BioSolutions Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Emergent BioSolutions's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.313/21.98
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Emergent BioSolutions's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=11.656/131.7762*131.7762
=11.656

Current CPI (Mar. 2024) = 131.7762.

Emergent BioSolutions Quarterly Data

Book Value per Share CPI Adj_Book
201406 9.580 100.560 12.554
201409 10.605 100.428 13.915
201412 11.897 99.070 15.825
201503 12.968 99.621 17.154
201506 12.931 100.684 16.924
201509 13.870 100.392 18.206
201512 15.375 99.792 20.303
201603 15.036 100.470 19.721
201606 14.808 101.688 19.189
201609 12.051 101.861 15.590
201612 13.930 101.863 18.021
201703 13.936 102.862 17.853
201706 13.436 103.349 17.132
201709 13.456 104.136 17.028
201712 15.603 104.011 19.768
201803 14.349 105.290 17.959
201806 16.060 106.317 19.906
201809 16.507 106.507 20.423
201812 17.355 105.998 21.576
201903 17.003 107.251 20.891
201906 16.961 108.070 20.682
201909 18.213 108.329 22.155
201912 18.949 108.420 23.031
202003 18.610 108.902 22.519
202006 20.124 108.767 24.381
202009 20.048 109.815 24.057
202012 22.400 109.897 26.860
202103 23.865 111.754 28.141
202106 23.860 114.631 27.429
202109 24.102 115.734 27.443
202112 27.801 117.630 31.144
202203 28.380 121.301 30.831
202206 28.687 125.017 30.238
202209 29.335 125.227 30.869
202212 26.147 125.222 27.516
202303 22.286 127.348 23.061
202306 17.040 128.729 17.443
202309 12.612 129.860 12.798
202312 11.406 129.419 11.614
202403 11.656 131.776 11.656

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emergent BioSolutions  (STU:ER4) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Emergent BioSolutions Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions (STU:ER4) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines